Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

Introduction The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the effect of this agent on cardiometabolic parameters in subjects with T2DM varied in relation to the concomitant presen...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2022-03, Vol.13 (3), p.453-464
Main Authors: Nikolic, Dragana, Patti, Angelo M., Giglio, Rosaria V., Chianetta, Roberta, Castellino, Giuseppa, Magán-Fernández, Antonio, Citarrella, Roberto, Papanas, Nikolaos, Janez, Andrej, Stoian, Anca Pantea, Rizvi, Ali A., Rizzo, Manfredi
Format: Article
Language:English
Subjects:
Antidiabetics
Body mass index
Cardiology
Complications and side effects
Diabetes
Dosage and administration
Drug therapy
Endocrinology
GLP-1 receptor agonists
Health aspects
Internal Medicine
Liraglutide
Medicine
Medicine & Public Health
Obesity
Original Research
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the effect of this agent on cardiometabolic parameters in subjects with T2DM varied in relation to the concomitant presence of obesity. Methods One hundred thirty-five subjects (78 men and 57 women; age: 62 ± 10 years) naïve to incretin-based therapies were treated with low-dose liraglutide (1.2 mg/day) as an add-on to metformin for 18 months. Patients were divided into two subgroups based on their body-mass index (BMI): (a) obese (BMI ≥ 30) and (b) non-obese (BMI 
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-022-01217-z